Funding Programs

Amplify was created in 2019 to address the funding gap between basic research or drug discovery and clinical proof-of-concept. Amplify focuses on enhancing the value of pre-commercial projects prior to their commercialization. 

The Innovation Discovery Grants (IDG) program aims to stimulate new inventive concepts, identify commercially significant scientific strength areas, and accelerate the commercialization of Mass General Brigham intellectual assets.

Mass General Brigham is one of several institutions participating in Lab eN2, a three-way collaboration with Novo Nordisk and Evotec, focused on drug discovery in the cardiometabolic space.

Exploration of novel research for drug discovery and clinical applications.

Pfizer’s Centers for Therapeutic Innovation (CTI) program for collaborative development of novel biotherapeutics focuses on accessing cutting-edge science and innovative discoveries aligned with Pfizer’s current core research areas of oncology, inflammation & immunology, rare diseases, and internal medicine.

The Sanofi iAwards Program is designed to accelerate innovative early-stage, disease-relevant research by funding translational research ideas that can contribute to the early-stage innovation pipeline and ultimately address unmet clinical needs.

Collaboration providing early-stage funding and scientific expertise to selected projects across oncology, immunology and neurology.